Weighing Access and Affordability - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Weighing Access and Affordability
Policymakers must balance fundamental issues involving access to medicines and pricing.


Pharmaceutical Technology
Volume 36, Issue 11, pp. 30

Of course, this conclusion begs the questions: Why were more new cancer drugs approved in the US than in Europe, and among the 29 drugs common to both regions, why were all of them approved and marketed first in the US? The answer is that approvals are, in part, a function of both regulatory policy (e.g., access to priority review and accelerated approval procedures) as well as institutional features, such as whether an environment is more conducive to the marketing of products. The US has fewer price controls and has less institutionalization of cost-effectiveness assessments as a possible barrier to market access. Consequently, pharmaceutical companies are more likely to seek approval and market their products first in the US.

If the following policy goal is presupposed—that is, to maximize aggregate health outcomes subject to a budget constraint—then the European scenario of granting less access to medicines deemed to offer less value (i.e., less cost-effective) may make sense. This scenario, however, is a societal or payer perspective and may not represent the best interests of individual patients, who are unlikely to care much about average, aggregated data. To them, having more immediate access offers hope, a chance at an extension of life, or an improvement in quality of life.

There may be a trade-off between access and pricing: greater access at the expense of higher, possibly unaffordable prices to patients. It's a "cruel irony."

Kenneth I. Kaitin, PhD, is professor and director, and Joshua P. Cohen, PhD, is assistant professor, both at the Tufts Center for the Study of Drug Development, Tufts School of Medicine,

Reference

1. K.I. Kaitin, Ed., "US Offers Patients Faster, Greater Access to Cancer Drugs than Europe," Tufts CSDD Impact Report 14 (4), 1–4 (2012).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here